ICCC vs ELAN vs ZTS vs PCRX vs PAHC

For growth investors, ImmuCell Corporation (ICCC) is the stronger pick with 51.

6% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). Zoetis Inc. (ZTS) offers the better valuation at 13. 8x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Elanco Animal Health Incorporated (ELAN) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 13. 8x versus Pacira BioSciences, Inc. at 144. 7x. On forward P/E, Pacira BioSciences, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 0. 99x versus Phibro Animal Health Corporation's 1. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +57.

5%, compared to -62. 0% for Pacira BioSciences, Inc. (PCRX). Over 10 years, the gap is even starker: PAHC returned +113. 5% versus PCRX's -52. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ImmuCell Corporation (ICCC) is the lower-risk stock at 0.

38β versus Elanco Animal Health Incorporated's 1. 46β — meaning ELAN is approximately 289% more volatile than ICCC relative to the S&P 500. On balance sheet safety, ImmuCell Corporation (ICCC) carries a lower debt/equity ratio of 55% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ImmuCell Corporation (ICCC) is pulling ahead at 51.

6% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, ICCC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus -8. 1% for ImmuCell Corporation — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus -6. 2% for ICCC. At the gross margin level — before operating expenses — PCRX leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 0. 99x versus Phibro Animal Health Corporation's 1. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pacira BioSciences, Inc. (PCRX) trades at 8. 1x forward P/E versus 22. 4x for Elanco Animal Health Incorporated — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 61. 3% to $133. 57.

In this comparison, ZTS (2.

4% yield), PAHC (1. 2% yield) pay a dividend. ICCC, ELAN, PCRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zoetis Inc.

(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88), 2. 4% yield). Both have compounded well over 10 years (ZTS: +97. 8%, ELAN: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ICCC is a small-cap high-growth stock; ELAN is a mid-cap quality compounder stock; ZTS is a mid-cap deep-value stock; PCRX is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock. ZTS, PAHC pay a dividend while ICCC, ELAN, PCRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.